Abhishek Tripathi, MD
Medical Oncology · Duarte, CANPI 1568750032
Payments from drug & device makers
Across 269 payments — averaging $7092.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$861K
- Seagen Inc.$328K
- Eli Lilly$225K
- Exelixis Inc.$124K
- Merck$90K
- Amgen$79K
- plus $201K from 20 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 68 | $861,278 |
| Seagen Inc. | 44 | $327,693 |
| Eli Lilly | 6 | $224,553 |
| Exelixis Inc. | 73 | $124,155 |
| Merck | 24 | $89,566 |
| Amgen | 3 | $79,205 |
| Genentech, Inc. | 4 | $57,082 |
| EMD Serono, Inc. | 3 | $50,849 |
| Clovis Oncology, Inc. | 7 | $24,750 |
| Janssen Research & Development, LLC | 1 | $21,000 |
| EMD Serono Research & Development Institute, Inc. | 1 | $15,101 |
| Sanofi | 5 | $9,937 |
| Gilead | 4 | $6,557 |
| Foundation Medicine, Inc. | 5 | $5,962 |
| Astellas Pharma Global Development | 3 | $2,379 |
| Organon | 1 | $2,300 |
| Bayer | 1 | $2,226 |
| Aadi Bioscience, Inc. | 1 | $1,500 |
| Janssen Scientific Affairs, LLC | 1 | $818 |
| AVEO Pharmaceuticals, Inc. | 6 | $711 |
| E.r. Squibb & Sons, L.L.C. | 1 | $79 |
| Eisai Inc. | 3 | $68 |
| Urogen Pharma, Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $21 |
| Astellas Pharma US Inc | 1 | $16 |
| Novartis | 1 | $16 |
How this compares
$1,907,845 in reported general payments places this provider in the 85th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Duarte
- Marwan FakihDuarte$24.2M
- Sumanta PalDuarte$15.9M
- Daneng LiDuarte$12.4M
- Tanya DorffDuarte$8.7M
- Erminia MassarelliDuarte$7.2M
- Joseph ChaoDuarte$4M
- Karen ReckampDuarte$3.1M
- Yan XingDuarte$2.8M
- Adam RockDuarte$2.7M
- Marianna KoczywasDuarte$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.